← 返回前沿论文

肿瘤浸润性 B 细胞在人肝内胆管癌中的免疫抑制作用及其在化疗免疫治疗结局中的作用

英文原题:Immunosuppressive contribution of tumour-infiltrating B cells in human intrahepatic cholangiocarcinoma and their role in chemoimmunotherapy outcome.

PubMed 2026/05/12(内容时间) Gut Q1 · IF 24.6(JCR 2025)

研究概要

iCCA 的特征是深度免疫抑制的 TME,通过可溶性因子和细胞相互作用损害 B 细胞功能。我们的研究结果将 B 细胞确定为生物标志物和治疗靶点,支持恢复 B 细胞功能和促进成熟 TLS 以增强 iCCA 免疫治疗应答的策略。

研究思路结论见上方概要

肝内胆管癌(iCCA)是一种高度侵袭性的胆道癌,预后差,且具有复杂的肿瘤微环境(TME),目前对其认识仍不充分。

本研究旨在探讨B淋巴细胞的表型和分子特征、其与TME的相互作用及其预后意义。

iCCA患者肿瘤、瘤周和外周血中的B细胞区室通过多模态单细胞技术进行了分析。在计算机中探索了B细胞与iCCA TME的相互作用组,并通过离体实验评估了与癌症相关成纤维细胞(CAFs)和肿瘤细胞的相互作用对B细胞生物学的影响。还评估了晚期iCCA化疗免疫治疗期间B细胞的调节。

B细胞在邻近无瘤组织中富集,形成成熟的三级淋巴结构(TLS),与更好的预后相关。相反,肿瘤浸润B细胞稀少、不成熟,并表现出效应功能降低和免疫抑制特征增加。与肿瘤细胞或CAFs共培养损害了B细胞的分化和功能,包括外周B细胞中BAFFR的下调。IL-6和TGF-β成为B细胞功能障碍的主要驱动因素;双重阻断恢复了B细胞的活化和分化。循环BAFFR+ B细胞频率升高和超扩增克隆型与改善的化学免疫治疗反应相关。

展开英文摘要原文

BACKGROUND: Intrahepatic cholangiocarcinoma (iCCA) is a highly aggressive biliary tract cancer with a poor prognosis and a complex tumour microenvironment (TME) that remains poorly understood. OBJECTIVE: This study aimed to investigate the phenotypic and molecular characteristics of B lymphocytes, their interactions with the TME and their prognostic implications. DESIGN: B-cell compartments in the tumour, peritumour, and peripheral blood of iCCA patients were analysed using multimodal single-cell technologies. The B-cell interactome with the iCCA TME was explored in silico, and ex vivo assays assessed the impact of interactions with cancer-associated fibroblasts (CAFs) and tumour cells on B-cell biology. B-cell modulation during chemoimmunotherapy in advanced iCCA was also evaluated. RESULTS: B cells were enriched in adjacent tumour-free tissues and formed mature tertiary lymphoid structures (TLS), correlating with better prognosis. Conversely, tumour-infiltrating B cells were scarce, immature and displayed reduced effector function with increased immunosuppressive features. Coculture with tumour cells or CAFs impaired B-cell differentiation and function, including downregulation of BAFFR in peripheral B cells. IL-6 and TGF-β emerged as major drivers of B-cell dysfunction; dual blockade restored B-cell activation and differentiation. Elevated frequencies of circulating BAFFR + B cells and hyperexpanded clonotypes were linked to improved chemoimmunotherapy response. CONCLUSIONS: iCCA is characterised by a profoundly immunosuppressive TME that impairs B-cell function through soluble factors and cellular interactions. Our findings identify B cells as biomarkers and therapeutic targets, supporting strategies to restore B-cell function and promote mature TLS to enhance immunotherapy responsiveness in iCCA.

论文信息

作者
Milardi G、Franceschini B、Camisaschi C、Puccio S、Costa G、Soldani C、Uva P、Cangelosi D
第一作者单位
Hepatobiliary Immunopathology Lab, Department of Gastroenterology, IRCCS Humanitas Research Hospital, Rozzano (MI), Italy.Italy
通讯作者单位
Department of Biomedical Sciences, Humanitas University, Pieve Emanuele (MI), Italy ana.lleo@humanitas.it.Italy
期刊
Gut2026 May 12
原文标识
PubMed 40889886 · DOI 10.1136/gutjnl-2025-334861